Electroretinogram Market: Current Analysis and Forecast (2023-2030)

Electroretinogram (ERG) is a non-invasive technique that measures the electrical response of the retina, providing valuable insights into retinal function and health. It plays a crucial role in the diagnosis, monitoring, and management of various retinal disorders, including retinitis pigmentosa, macular degeneration, and diabetic retinopathy.

The ERG market is a growing sector within ophthalmic diagnostics, driven by the increasing prevalence of retinal diseases and the need for accurate and efficient diagnostic tools. For instance, the World Health Organization (WHO) estimates that approximately 253 million people worldwide live with visual impairment, with a significant portion attributed to retinal diseases. Technological advancements, such as improved electrode design and signal processing algorithms, have enhanced the accuracy and efficiency of ERG testing. With a focus on clinical diagnostics and research applications, the ERG market is expected to continue expanding as healthcare providers and researchers recognize its importance in delivering personalized patient care and advancing our understanding of retinal health.

The Electroretinogram Market is expected to grow at a strong CAGR of ~6.5% during the forecast period owing to the increasing prevalence of retinal diseases and advancements in ERG technology. Moreover, the growing demand for early disease detection, rising research activities, and increasing healthcare expenditure around the globe are also helping the market grow at a strong growth rate.

Based on type, the electroretinogram market is segmented into full-field flash ERG (ffERG), pattern ERG (PERG), and multifocal ERG (mfERG). Amongst these, the ffERG segment dominated the market in 2022. This is because ffERG is a widely used and established technique that measures the overall electrical activity of the entire retina. It is valuable in diagnosing and monitoring various retinal disorders, including inherited retinal diseases like retinitis pigmentosa. Due to its broad application and established usage, ffERG is expected to continue as a significant segment in the ERG market.

By product, the market is bifurcated into fixed and portable. Among these, fixed captured the majority share of the electroretinogram market in 2022. The major share of the fixed electroretinogram can be attributed to the capabilities and features offered such as advanced features, higher resolution, and precise measurements due to their larger size and dedicated design. These devices are typically equipped with sophisticated amplifiers, filters, and data acquisition systems, allowing for more accurate and reliable recordings of retinal responses.

Based on application, the market is bifurcated into clinical diagnostic and research. Clinical diagnostic is expected to dominate the market as it caters to the immediate needs of patients seeking diagnosis, monitoring, and management of retinal diseases. The growing prevalence of retinal disorders and the increasing demand for early detection and personalized treatment options are likely to drive the demand for ERG in clinical settings.

For a better understanding of the market adoption of the electroretinogram industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), and Rest of World. North America dominated the electroretinogram market in 2022 due to relatively high prevalence of retinal diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa. This increased disease burden created a demand for accurate and efficient diagnostic tools like ERG, driving the market growth. of electroretinograms in North America over the forecasted period.

Some of the major players operating in the market include: LKC Technologies, Inc.; Diagnosys LLC; Electro-Diagnostic Imaging, Inc.; Diopsys, Inc.; Metrovision; Roland Consult Stasche & Finger GmbH; CSO Italia; Konan Medical USA, Inc.; NIDEK Co., Ltd.; Topcon Corporation